Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.
Research Interests

Papers共 147 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
1769P Safety and Efficacy with Vimseltinib in Patients (pts) with Tenosynovial Giant Cell Tumor (TGCT) Who Received No Prior Anti–colony-Stimulating Factor 1 (CSF1) Therapy: Ongoing Phase II Study
C. Serrano,J-Y. Blay, P. Rutkowski, H. Gelderblom, S. Stacchiotti,A. Falcon Gonzalez, J. Desai, A. Le Cesne,V. Ferraresi,E. Palmerini,B.A. Wilky, A.J. Wagner,N.M. Bernthal, M. van de Sande, S. Narasimhan,B. Harrow, M.G. Sharma,R. Ruiz-Soto, M.L. Sherman,W.D. Tap
Annals of Oncology (2024)
Cited0Views0Bibtex
0
0
53O Results from a Phase II Part I Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in Patients with Advanced Refractory Sarcoma
S. Pollack,A.P. Conley,W.D. Tap,C-C. Yen, J. Charlson, L. Davis, A. Chalmers,M. Druta,E. Loggers, J.S. Grewal,G. Falchook, B. Schulte, T. Yau, A. Kim,H.H.F. Loong, S. George, B. Setty, L. Mascarenhas, G.M. Cote,B. Wilky
ESMO Open (2024)
Cited0Views0Bibtex
0
0
Behaving Badly: Thinking Outside the Box for Treatment of Sarcoma in a Challenging Location
Breelyn A. Wilky,Ryan M. Lanning
International Journal of Radiation OncologyBiologyPhysicsno. 4 (2024): 1055-1056
Cited0Views0WOSBibtex
0
0
Load More
Author Statistics

#Papers: 149

#Citation: 1968

H-Index: 23

G-Index: 42

Sociability: 7

Diversity: 2

Activity: 115

  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn